ClinicalTrials.Veeva

Menu
P

Preferred Research Partners, Inc. | Little Rock, AR

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Relamorelin
Vonoprazan
Linaclotide
Daridorexant
JZP-110
Atogepant
SPN-812
Dapagliflozin
BMS-512148
CIN-102

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

23 of 100 total trials

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)

A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized...

Enrolling
Generalized Anxiety Disorder
Drug: MM120 (LSD D-Tartrate)
Other: Placebo

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Major Depress...

Enrolling
Major Depressive Disorder
Other: Placebo
Drug: MM120 (LSD D-Tartrate)

The primary objective of this study is to assess the efficacy of vonoprazan 20 mg once daily (QD) compared to placebo QD in the number of participant...

Enrolling
Eosinophilic Esophagitis
Drug: Placebo
Drug: Vonoprazan

The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severe...

Enrolling
Ulcerative Colitis Chronic
Ulcerative Colitis
Drug: Placebo
Drug: Eltrekibart

Migraine is a disease that most often causes moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompa...

Enrolling
Chronic Migraine
Drug: Atogepant
Drug: Placebo for Atogepant

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have o...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Retatrutide

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vo...

Enrolling
Episodic Migraine
Drug: Placebo-Matching Atogepant
Drug: Atogepant

This Phase 2 study (protocol number VLS-01-203) will determine the efficacy, safety, and tolerability of short-term treatment with a VLS-01 transmuco...

Enrolling
Treatment Resistant Depression
Drug: VLS-01-BU Placebo
Drug: VLS-01-203 BU

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopa...

Active, not recruiting
Idiopathic Gastroparesis
Drug: Placebo
Drug: CIN-102 Dose 15mg

This is a randomized, double-blind, placebo-controlled, parallel-dosing, multi-center study to evaluate the efficacy and safety of Rencofilstat as ev...

Active, not recruiting
Fibrosis, Liver
Nonalcoholic Steatohepatitis (NASH)
Drug: Rencofilstat
Drug: Placebo

The purpose of this study is to assess the change in 24-hour ambulatory blood pressure monitoring (ABPM) between baseline (Day 0) and Day 120 followi...

Enrolling
Hypogonadism
Drug: Natesto

To evaluate long-term safety exposure

Active, not recruiting
Attention Deficit/Hyperactivity Disorder
Drug: Centanafadine Hydrochloride

The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep...

Invitation-only
OSA
Drug: Aroxybutynin and Atomoxetine
Status recently updated

This study assesses the efficacy, safety, and pharmacokinetics of multiple-dose oral administration of daridorexant in pediatric subjects aged 10 to...

Enrolling
Active, not recruiting
Insomnia
Drug: Daridorexant 10 mg
Drug: Daridorexant 25 mg

This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

Enrolling
Attention-Deficit/Hyperactivity Disorder
Drug: Placebo
Drug: 100mg SPN-812

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vo...

Invitation-only
Migraine Prophylaxis
Drug: Atogepant

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Invitation-only
Migraine
Drug: Ubrogepant

The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with plac...

Enrolling
Depressive Disorder, Major
Drug: Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug: Placebo

A migraine is a moderate to severe headache typically on one side of the head. A migraine attack is a headache that may be accompanied by throbbing,...

Enrolling
Migraine
Drug: Ubrogepant
Drug: Placebo for Ubrogepant

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Enrolling
Migraine
Drug: Placebo-Matching Ubrogepant
Drug: Ubrogepant

Trial sponsors

AbbVie logo
Apnimed logo
Janssen (J&J Innovative Medicine) logo
Allergan logo
Ferring logo
Shire logo
Idorsia Pharmaceuticals logo
Jazz Pharmaceuticals logo
Lilly logo
M

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems